# Project Charter: Connectome-GNN-Suite

## Project Overview

**Project Name:** Connectome-GNN-Suite  
**Project Lead:** Daniel Schmidt  
**Start Date:** January 2025  
**Current Version:** 0.1.0  
**Status:** Active Development  

## Mission Statement

To democratize access to state-of-the-art graph neural network tools for brain connectivity analysis, enabling researchers worldwide to unlock insights from the most complex network in nature - the human brain.

## Problem Statement

### Current Challenges
1. **Fragmented Tools**: Neuroscience researchers lack unified tools for applying modern graph neural networks to brain connectivity data
2. **Scale Limitations**: Existing tools cannot handle the massive scale of modern connectome datasets (100B+ edges)
3. **Accessibility Barriers**: Advanced GNN techniques require deep technical expertise, limiting adoption
4. **Reproducibility Crisis**: Lack of standardized benchmarks and evaluation protocols
5. **Clinical Translation Gap**: Research tools are not designed for clinical deployment and regulatory compliance

### Market Need
- **Research Community**: 10,000+ neuroscientists working with connectome data globally
- **Clinical Applications**: Growing demand for AI-assisted diagnosis in neurology and psychiatry
- **Pharmaceutical Industry**: Need for objective biomarkers in drug development
- **Educational Sector**: Training tools for next-generation computational neuroscientists

## Project Scope

### In Scope
- **Core Framework**: Scalable GNN implementation for brain connectivity analysis
- **Data Integration**: Support for major neuroimaging datasets (HCP, ADNI, ABIDE, UK Biobank)
- **Model Library**: Pre-implemented architectures optimized for brain data
- **Visualization Tools**: Interactive 3D brain network visualization and interpretation
- **Benchmarking Suite**: Standardized evaluation protocols for reproducible research
- **Clinical Tools**: Features supporting translation to clinical applications
- **Documentation**: Comprehensive tutorials, API documentation, and best practices

### Out of Scope
- **Raw Image Processing**: Primary neuroimaging preprocessing (defer to FSL, FreeSurfer)
- **Statistical Analysis**: Traditional connectivity analysis (defer to existing tools)
- **Clinical Certification**: Regulatory approval (support users in their certification efforts)
- **Hardware Development**: Specialized computing hardware for brain analysis

### Success Criteria

#### Technical Success Metrics
- **Performance**: Achieve state-of-the-art results on standard brain connectivity benchmarks
- **Scalability**: Handle graphs with 100,000+ nodes and 100M+ edges efficiently
- **Usability**: Enable non-experts to apply advanced GNN techniques in <1 day
- **Reliability**: 99.9% uptime for core functionality, comprehensive test coverage
- **Interoperability**: Seamless integration with major neuroimaging workflows

#### Adoption Success Metrics
- **Community Growth**: 1,000+ GitHub stars, 500+ monthly active users by end of 2025
- **Academic Impact**: Enable 50+ peer-reviewed publications within 2 years
- **Clinical Translation**: Support 10+ clinical pilot studies by end of 2026
- **Educational Impact**: Train 1,000+ researchers through tutorials and workshops

#### Business Success Metrics
- **Sustainability**: Secure ongoing funding through grants, partnerships, and support services
- **Ecosystem Development**: Foster a community of contributors and third-party extensions
- **Industry Adoption**: Partnerships with 5+ pharmaceutical or medical device companies

## Stakeholder Analysis

### Primary Stakeholders

#### Computational Neuroscientists
- **Needs**: Advanced GNN tools, scalable implementations, reproducible benchmarks
- **Success Criteria**: Publish high-impact research, accelerate discovery timeline
- **Engagement**: Direct collaboration, feature requests, code contributions

#### Clinical Researchers
- **Needs**: Regulatory-compliant tools, interpretable models, clinical validation
- **Success Criteria**: Successful clinical trials, FDA/EMA approval pathways
- **Engagement**: Clinical advisory board, pilot studies, validation partnerships

#### Neuroimaging Centers
- **Needs**: Integration with existing workflows, training for staff, technical support
- **Success Criteria**: Improved research productivity, competitive advantage
- **Engagement**: Site visits, custom integrations, training programs

### Secondary Stakeholders

#### Funding Agencies (NIH, NSF, ERC)
- **Interests**: Open science, reproducible research, clinical translation
- **Influence**: High (funding decisions)
- **Engagement**: Grant proposals, progress reports, community metrics

#### Pharmaceutical Companies
- **Interests**: Drug development biomarkers, clinical trial optimization
- **Influence**: Medium (partnership opportunities)
- **Engagement**: Industry partnerships, sponsored research, consulting

#### Technology Partners (NVIDIA, AWS, Google)
- **Interests**: Showcase advanced computing capabilities, cloud adoption
- **Influence**: Medium (infrastructure support)
- **Engagement**: Technical partnerships, resource grants, co-marketing

### Risk Assessment

#### High-Risk Items
1. **Technical Complexity**: Managing massive graph computations within memory constraints
   - *Mitigation*: Hierarchical sampling, gradient checkpointing, extensive testing
2. **Regulatory Compliance**: Ensuring clinical tools meet regulatory standards
   - *Mitigation*: Early engagement with regulators, compliance-by-design approach
3. **Community Adoption**: Overcoming inertia in established research workflows
   - *Mitigation*: Exceptional documentation, training programs, key opinion leader engagement

#### Medium-Risk Items
1. **Competition**: Other frameworks or commercial solutions gaining market share
   - *Mitigation*: Focus on unique clinical translation and interpretability features
2. **Resource Constraints**: Limited funding or personnel for development
   - *Mitigation*: Diversified funding strategy, open-source community building
3. **Data Privacy**: Handling sensitive medical data across multiple institutions
   - *Mitigation*: Federated learning, differential privacy, security-first design

## Resource Requirements

### Personnel
- **Technical Lead** (1.0 FTE): Architecture design, code review, technical strategy
- **Senior Developers** (2.0 FTE): Core implementation, optimization, testing
- **Research Scientists** (1.5 FTE): Algorithm development, validation, publications
- **Clinical Liaison** (0.5 FTE): Clinical requirements, regulatory guidance
- **Community Manager** (0.5 FTE): Documentation, user support, ecosystem development

### Infrastructure
- **Computing Resources**: Multi-GPU development servers, cloud compute credits
- **Data Storage**: Secure storage for large neuroimaging datasets
- **Collaboration Tools**: GitHub, Slack, documentation platform
- **Testing Infrastructure**: Continuous integration, automated testing, benchmarking

### Funding Requirements
- **Year 1**: $500k (personnel, infrastructure, travel)
- **Year 2**: $750k (scaling team, additional compute, conferences)
- **Year 3**: $1M (clinical partnerships, enterprise features, sustainability)

## Governance Structure

### Decision Making
- **Technical Decisions**: Core development team with community input
- **Strategic Decisions**: Steering committee with key stakeholders
- **Feature Prioritization**: User feedback, clinical needs, research impact

### Intellectual Property
- **Open Source License**: MIT License for maximum adoption
- **Patent Policy**: Defensive patents only, open licensing for research use
- **Contribution Agreement**: Contributor License Agreement for code contributions

### Quality Assurance
- **Code Review**: All changes require peer review and automated testing
- **Documentation Standards**: Comprehensive API docs, tutorials, examples
- **Release Process**: Semantic versioning, beta testing, community feedback

## Communication Plan

### Internal Communication
- **Weekly Standups**: Development team progress and coordination
- **Monthly All-Hands**: Broader team updates and strategic alignment
- **Quarterly Reviews**: Stakeholder updates and planning sessions

### External Communication
- **Community Updates**: Monthly newsletter, blog posts, social media
- **Academic Engagement**: Conference presentations, workshop tutorials
- **Industry Outreach**: Partner meetings, customer visits, trade shows

### Documentation Strategy
- **User Documentation**: Getting started guides, tutorials, best practices
- **Developer Documentation**: API reference, architecture guides, contribution guide
- **Scientific Documentation**: Methodology papers, validation studies, benchmarks

## Timeline & Milestones

### Phase 1: Foundation (Q1-Q2 2025)
- Core architecture implementation
- HCP dataset integration
- Basic visualization tools
- Community building initiation

### Phase 2: Enhancement (Q3-Q4 2025)
- Multi-modal data support
- Advanced visualization
- Clinical validation studies
- Partnership development

### Phase 3: Translation (Q1-Q2 2026)
- Regulatory compliance features
- Enterprise deployment tools
- Large-scale clinical trials
- Commercial sustainability

### Phase 4: Scale (Q3-Q4 2026)
- Global deployment
- Foundation model development
- Ecosystem expansion
- Long-term sustainability

## Success Monitoring

### Key Performance Indicators (KPIs)
- **Technical**: Performance benchmarks, scalability metrics, reliability measures
- **Adoption**: User growth, download statistics, contribution metrics
- **Impact**: Publication count, clinical studies, industry partnerships
- **Community**: Forum activity, issue resolution time, satisfaction surveys

### Reporting Schedule
- **Monthly**: Technical progress, user metrics, issue resolution
- **Quarterly**: Strategic progress, stakeholder updates, financial status
- **Annually**: Comprehensive review, impact assessment, strategic planning

---

**Charter Approval**

This charter represents the foundational agreement for the Connectome-GNN-Suite project. It will be reviewed quarterly and updated as needed to reflect changing requirements and opportunities.

**Approved by:**
- Technical Lead: Daniel Schmidt
- Principal Investigator: [To be assigned]
- Funding Agency Representative: [To be assigned]

**Date:** January 2025  
**Version:** 1.0  
**Next Review:** April 2025